ライフサイエンスコーパス: imipenem

1 her resistance or intermediate resistance to imipenem).

2 ent reaction intermediate with the substrate imipenem.

3 of drugs like ceftazidime, penicillins, and imipenem.

4 onferring resistance to all beta-lactams but imipenem.

5 esting susceptibility of enterococci against imipenem.

6 es, as did 130 of the 162 (80%) treated with imipenem.

7 ccurately predicted the in vitro activity of imipenem.

8 species against cefoxitin, doxycycline, and imipenem.

9 interpretive category was most variable for imipenem.

10 d the hydrolytic activity for penicillin and imipenem.

11 ed hydrolytic activity for cephaloridine and imipenem.

12 t were resistant to most beta-lactams except imipenem.

13 actual two- to fourfold increases in MICs of imipenem.

14 e classification of isolates as resistant to imipenem.

15 only 40% of the strains were susceptible to imipenem.

16 erate intrinsic resistance to ampicillin and imipenem.

17 was 69%-73% for ceftazidime and 41%-50% for imipenem.

18 the addition of vancomycin to ampicillin and imipenem.

19 entified drugs that restored the activity of imipenem.

20 hat were not susceptible to meropenem and/or imipenem.

21 -1 and GES-5 beta-lactamases in complex with imipenem.

22 ient for manifestation of resistance against imipenem.

23 atment with fosfomycin (2 g/6 hours IV) plus imipenem (1 g/6 hours IV) was started and monitored.

24 ensive care units: Doripenem, 0.5%, 8%, 78%; imipenem, 1, 16, 75%; and meropenem, 1, 16, 82%.

25 rcent susceptibility): Doripenem, 1, 8, 69%; imipenem, 2, 16, 67%; and meropenem, 1, 32, 70%; and by

26 cept for Vitek testing (major error rate for imipenem, 20%).

27 eratitis isolates was least for colistin and imipenem (56.52% each).

28 00 versus 13%), vancomycin (100 versus 57%), imipenem (94 versus 2%), and high levels of gentamicin (

29 Monitoring the turnover of imipenem (a carbapenem) by GES-1 (Gly-170) revealed the

30 coli growth on increasing concentrations of imipenem, a carbapenem antibiotic.

31 Finally, superimposition of the imipenem-acylated complex with PBP 5 in complex with a b

32 minimum inhibitory concentrations (MICs) of imipenem against clinical isolates of Eschericia coli an

33 curate predictor of the in vitro activity of imipenem against E. faecalis.

34 Treatment with either ampicillin or imipenem alone or in combination with vancomycin resulte

35 obial resistance against aminoglycosides and imipenem also was detected.

36 ment by interpretive category was lowest for imipenem and amikacin.

37 n, categorical agreement (CA) for penicillin-imipenem and ampicillin-imipenem tested with E. faecalis

38 Imipenem and ceftazidime have different specificities fo

39 Imipenem and ciprofloxacin significantly reduced the num

40 Survival was significantly improved by imipenem and ciprofloxacin.

41 a prolonged (5-month) course of intravenous imipenem and gentamicin.

42 completely with cefoxitin and partially with imipenem and is absent with cloxacillin, is consistent w

43 s for Disease Control and Prevention against imipenem and meropenem by agar dilution, disk diffusion,

44 Imipenem and meropenem induced faster killing of E. coli

45 escence on the enzyme, and its reaction with imipenem and meropenem revealed biphasic fluorescence ti

46 For Enterobacteriaceae, the imipenem and meropenem test methods produced low numbers

47 amikacin, tigecycline, and the carbapenems (imipenem and meropenem); 90.8% of Acinetobacter baumanni

48 errors when P. aeruginosa was tested against imipenem and meropenem, except for Vitek testing (major

49 ermeability of two zwitterionic carbapenems, imipenem and meropenem, measured using liposome permeati

50 the differences in the binding properties of imipenem and meropenem, two potent antibiotics of the ca

51 pproximately 1% between penicillins and both imipenem and meropenem, whereas a single study found a c

52 ross-reactivity between penicillins and both imipenem and meropenem, while a single study found a 5.5

53 surable activity with carbapenems, including imipenem and meropenem.

54 were conducted on ImiS and its reaction with imipenem and meropenem.

55 phalothin analogue and (ii) the carbapenems, imipenem and meropenem.

56 ntain a bulky 6(7)alpha substituent, such as imipenem and moxalactam, actually inhibit serine beta-la

57 44 and 1.10 kcal/mol of strain introduced by imipenem and moxalactam, respectively, relative to the w

58 me's thermodynamic stability in complex with imipenem and moxalactam.

59 Using FDA susceptibility breakpoints for imipenem and NCCLS breakpoints for penicillin and ampici

60 erred levels of resistance to the carbapenem imipenem and other beta-lactams.

61 Meropenem is closely related to imipenem and was recently approved for use in children.

62 were observed with Proteus mirabilis versus imipenem and with Klebsiella pneumoniae versus ofloxacin

63 susceptibility (piperacillin-tazobactam and imipenem) and others toward false resistance (aztreonam,

64 active (1-Zn), product-inhibited (1-Zn plus imipenem), and inactive (2-Zn) forms.

65 oducibility among MICs was most variable for imipenem, and agreement by interpretive category was low

66 r intermediate to cefoxitin, clarithromycin, imipenem, and amikacin.

67 a selective medium incorporating vancomycin, imipenem, and amphotericin B.

68 new non-beta-lactam inhibitors (MK-7655 with imipenem, and avibactam with ceftazidime and ceftaroline

69 ducing strains were susceptible to cefepime, imipenem, and ertapenem but that with a high inoculum, m

70 amase enzyme and the carbapenems, meropenem, imipenem, and ertapenem, have been studied by Raman micr

71 sistance to third-generation cephalosporins, imipenem, and fluoroquinolones in Escherichia coli, Kleb

72 by resistance to piperacillin, ceftazidime, imipenem, and FQ.

73 d, tigecycline, and vancomycin; minocycline, imipenem, and meropenem were also highly active (>92% su

74 a-lactams, aztreonam, cefepime, ceftazidime, imipenem, and piperacillin-tazobactam, were tested.

75 as resistant to ceftazidime, azlocillin, and imipenem, and sensitive to tobramycin and ciprofloxacin.

76 ible or intermediate to amikacin, cefoxitin, imipenem, and the fluoroquinolones and sulfonamides but

77 ciprofloxacin, clarithromycin, doxycycline, imipenem, and trimethoprim-sulfamethoxazole in each of f

78 vitro activities of penicillin, ampicillin, imipenem, and vancomycin against 201 blood isolates of E

79 treatment with a combination of ampicillin, imipenem, and vancomycin was compared with that of two-d

80 r ceftazidime; 71 and 19%, respectively, for imipenem; and 50 and 50%, respectively, for piperacillin

81 safety of the combination of fosfomycin and imipenem as rescue therapy for MRSA infective endocardit

82 1000 mg every 8 hrs 4-hr infusion, 92%, 97%; imipenem at 1000 mg every 8 h 3-h infusion, 77%, 83%; me

83 500 mg every 8 hrs 1-hr infusion, 73%, 79%; imipenem at 500 mg every 6 hrs 0.5-hr infusion, 62%, 69%

84 75 to 82% of the strains were susceptible to imipenem at an MIC of < or = 4 micrograms/ml.

85 covalent conjugates with benzyl penicillin, imipenem, aztreonam, and the siderophore-conjugated mono

86 d similarly with metronidazole or vancomycin-imipenem before or after receiving 5% dextran sodium sul

87 As a result, the protein architecture and imipenem binding mode remain unchanged.

88 6 containing meropenem and GNS-F7 containing imipenem) (bioMerieux Vitek, Inc., Durham, N.C.).

89 sm is susceptible to the aminoglycosides and imipenem but resistant to the cephalosporins and ciprofl

90 iscaviarum isolates were highly resistant to imipenem, but N. cyriacigeorgica, N. asteroides, N. farc

91 ting of penicillin or ampicillin, testing of imipenem by clinical laboratories probably is not necess

92 ro susceptibility to carbapenems (meropenem, imipenem) by MIC and disk diffusion methods and to compa

93 Since the susceptibility of enterococci to imipenem can be predicted by the results obtained by tes

94 Meropenem, imipenem, cefepime, ceftazidime (2 g every 8 hrs), and p

95 ns examined included cefoxitin-piperacillin, imipenem-cefotaxime, imipenem-ceftazidime, imipenem-pipe

96 idime, imipenem-piperacillin-tazobactam, and imipenem-cefoxitin.

97 cefoxitin-piperacillin, imipenem-cefotaxime, imipenem-ceftazidime, imipenem-piperacillin-tazobactam,

98 ll 29 positions indicates that hydrolysis of imipenem, cephaloridine and ampicillin has stringent seq

99 o specify active-site pockets that carry out imipenem, cephaloridine or ampicillin hydrolysis than on

100 sed antibiotics, including the beta-lactams, imipenems, cephalosporins, and glycopeptides.

101 results for two control strains tested with imipenem, chloramphenicol, and metronidazole indicated t

102 antimicrobials at standard doses: meropenem, imipenem-cilastatin, ceftazidime, cefepime, piperacillin

103 rba NP test that utilized intravenous (i.v.) imipenem-cilastatin, which is less expensive than refere

104 received buprenorphine (0.05 mg/kg, SC) and imipenem/cilastatin (14 mg/kg, SC) in 1.5 mL of warm sal

105 mes, as did 219 of 270 patients treated with imipenem/cilastatin (81%).

106 All 204 subjects underwent skin tests with imipenem/cilastatin and meropenem; 130 of them were skin

107 was conducted to compare clinafloxacin with imipenem/cilastatin as adjuncts in the management of com

108 iprofloxacin/metronidazole was compared with imipenem/cilastatin for treatment of complicated intra-a

109 y found a 5.5% rate of cross-reactivity with imipenem/cilastatin in subjects with T-cell-mediated hyp

110 ment failure who were initially treated with imipenem/cilastatin.

111 ding cefotetan, ticarcillin-clavulanate, and imipenem-cilastin.

112 richia coli PBP 5 as covalent complexes with imipenem, cloxacillin, and cefoxitin.

113 d puncture without antibiotics (CLP) or with imipenem (CLP + Abx).

114 antibiotics among piperacillin, ceftazidime, imipenem, colistine, and fluoroquinolones (FQ).

115 In addition, at high imipenem concentrations a number of residues that do not

116 y among non-Enterobacteriaceae were low, but imipenem demonstrated a sensitivity and specificity of 9

117 Imipenem demonstrated the most in vitro activity, and te

118 urveillance culture into broth containing an imipenem disk appeared to have the greatest sensitivity

119 The imipenem disk diffusion test appears compromised and sho

120 veillance specimens into broth containing an imipenem disk is an easy method for screening samples fo

121 creening medium, which involved using 10-mug imipenem disks, was investigated.

122 The crystal structure of PenA with imipenem docked into the active site suggests why this c

123 ng cell morphology changes (spheroplast with imipenem, filamentous cells with cefoxitin and ceftriaxo

124 in tryptic soy broth containing 2 microg/ml imipenem followed by plating to MacConkey agar (MAC) (me

125 MICs of imipenem for 68 unique clinical isolates of P. aeruginos

126 Mice received imipenem for antibiotic therapy, and groups were sacrifi

127 pecific than selective broth enrichment with imipenem for detection of KPC-producing K. pneumoniae an

128 the reformulated piperacillin-tazobactam and imipenem found on the AST-GN69 card, with no very major

129 owered the MIC breakpoints for meropenem and imipenem from 4 mg/liter to 1 mg/liter for Enterobacteri

130 d protect broad spectrum antibiotics such as imipenem from hydrolysis and thus extend their utility.

131 The isolates were susceptible to ampicillin, imipenem, gentamicin, amikacin, and trimethoprim-sulfame

132 ation with cefazolin, ceftriaxone, cefepime, imipenem, gentamicin, tigecycline, doxycycline, and rifa

133 susceptibility of Pseudomonas aeruginosa to imipenem has been shown to vary according to zinc concen

134 Although imipenem has in vitro activity against Enterococcus faec

135 ombinations using colistin, tigecycline, and imipenem have recently been associated with improved sur

136 sting active-site residues are optimized for imipenem hydrolysis.

137 xime, cefotetan, ceftriaxone, cefoxitin, and imipenem in addition to clindamycin but were resistant t

138 (ciprofloxacin, metronidazole, or vancomycin-imipenem) in drinking water or water alone in either pre

139 Its advantages over imipenem include greater activity against gram-negative

140 dicator of KPC resistance than meropenem and imipenem independently of the method used.

141 s (tobramycin, ciprofloxacin, aztreonam, and imipenem), indicating that this has potential clinical r

142 However, imipenem-induced bacterial killing resulted in significa

143 udomonas aeruginosa that were reported to be imipenem intermediate or resistant.

144 conformation of Tyr-105 hindered docking of imipenem into the active site of PenI.

145 metronidazole intravenously (CIP/MTZ IV) or imipenem intravenously (IMI IV) throughout their treatme

146 lo-beta-lactamases based on the reduction of imipenem (IP) or ceftazidime (TZ) MICs in the presence o

147 h in combination with subefficacious dose of imipenem (IPM) robustly lowered the bacterial burden in

148 arious concentrations]) and the beta-lactams imipenem (IPM), meropenem (MEM), ertapenem (ERT), and ce

149 Imipenem (IPM), meropenem (MEM), ertapenem (ERT), and do

150 Imipenem is approved by the U.S.

151 For example, MK-7655, in combination with imipenem, is in clinical development for the treatment o

152 The reaction of 1-Zn ImiS with imipenem leads to a product-bound species, coordinated t

153 ore part of the two compounds, being that of imipenem less bulky and hydrophobic.

154 in, ciprofloxacin, gatifloxacin, gentamicin, imipenem, levofloxacin, meropenem, tobramycin, and trime

155 ed in culture with the carbapenem antibiotic imipenem manifests markedly altered profiles of TNF-alph

156 erapy with the combination of ampicillin and imipenem may be effective for some strains of multidrug-

157 We next showed that the carbapenems (imipenem, meropenem, and doripenem) form long-lived acyl

158 iabetic patient was shown to be resistant to imipenem, meropenem, and ertapenem by disk diffusion sus

159 PC, NDM, and/or OXA carbapenemases, by using imipenem, meropenem, and ertapenem with LC-MS/MS assays.

160 Susceptibilities to piperacillin-tazobactam, imipenem, meropenem, and trovafloxacin remained virtuall

161 The imipenem, meropenem, doripenem, and ertapenem MIC50 valu

162 Minocycline, imipenem, meropenem, piperacillin, and piperacillin-tazo

163 It was resistant to imipenem (MIC, >256 mug/ml) and meropenem (MIC, 128 mug/

164 , and NDM, respectively, were susceptible to imipenem (MIC, </=1 mug/ml).

165 ited) and was 8- to 16-fold more potent than imipenem (MIC50, 1 microgram/ml; MIC90, 2 micrograms/ml)

166 with caution for detecting strains for which imipenem MICs are elevated.

167 e, ceftriaxone, ciprofloxacin, erythromycin, imipenem, minocycline, and trimethoprim-sulfamethoxazole

168 ydrolyzed ceftazidime poorly, and hydrolyzed imipenem more efficiently than ampicillin in contrast to

169 In both animal models vancomycin-imipenem most effectively prevented and treated colitis.

170 growth during exposure to colistin (n = 35), imipenem (n = 1) or ciprofloxacin (n = 1) in addition to

171 randomly received saline (n = 60), 20 mg/kg imipenem (n = 62), or 10 mg/kg ciprofloxacin (n = 60) ev

172 Staphylococcus aureus killed during imipenem or ceftazidime chemotherapy in mice elicited an

173 t observed without the antibiotic treatment (imipenem or ceftazidime).

174 a coli resistance to ampicillin, cefotaxime, imipenem or cephaloridine.

175 linically relevant antimicrobials (colistin, imipenem or ciprofloxacin) by Transposon Directed Insert

176 50.0%) followed by ciprofloxacin (32.6%) and imipenem or meropenem (28.7%).

177 cycline and ciprofloxacin paired with either imipenem or meropenem were the most active combinations

178 resistant to carbapenem antibiotics (either imipenem or meropenem).

179 s suggest that empirical therapy with either imipenem or metronidazole should be considered.

180 teriaceae infections treated with meropenem, imipenem, or doripenem.

181 distributions differed by unit type only for imipenem (p < .01).

182 icin (P<0.0001), tobramycin (P = 0.005), and imipenem (P<0.0001).

183 acylation rate constants for the antibiotics imipenem, penicillin G, and ceftriaxone.

184 pped from 2,000-fold to 70-fold with 4 mg of imipenem per kg given at the time of challenge.

185 , imipenem-cefotaxime, imipenem-ceftazidime, imipenem-piperacillin-tazobactam, and imipenem-cefoxitin

186 Of all of the combinations, imipenem/piperacillin-tazobactam provided the greatest s

187 ype beta-lactamase family, GES-1, turns over imipenem poorly, but the GES-5 beta-lactamase is an avid

188 ch is less expensive than reference standard imipenem powder, and an updated version of the Rosco Neo

189 eriaceae, nonsusceptibility to ertapenem and imipenem predicted the presence of bla(KPC) poorly, espe

190 Meropenem and imipenem provided high probabilities of achieving their

191 lysis of carbapenemases by PCR revealed that imipenem resistance but not meropenem resistance was ass

192 This occurred at the price of increased imipenem resistance in P aeruginosa, which remained susc

193 Imipenem resistance was detected in 65% of A. jandaei st

194 To investigate this overdetection of imipenem resistance, we tested 204 selected isolates fro

195 responsible for the initial overdetection of imipenem resistance.

196 4-bp insertion in the oprD gene resulted in imipenem resistance.

197 prevalence of ceftazidime-resistance and 5% imipenem-resistance, RMD platforms predicted susceptibil

198 (Tn2006) was found in most (66.7%, 40 of 68) imipenem-resistant A. baumannii (genospecies 2) and also

199 To reduce mortality, rapid identification of imipenem-resistant A. baumannii complex and early initia

200 Imipenem-resistant A. baumannii complex bacteremia speci

201 5 days or more increased risk of subsequent imipenem-resistant A. baumannii complex bacteremia.

202 microbial therapy, which was correlated with imipenem-resistant A. baumannii complex but not with any

203 n criteria, including 73 (24.5%) infected by imipenem-resistant A. baumannii complex.

204 istant isolates of Enterobacteriaceae and 43 imipenem-resistant and 21 meropenem-resistant isolates o

205 Seven imipenem-resistant and five meropenem-resistant isolates

206 from the Project ICARE collection plus five imipenem-resistant challenge strains at the Centers for

207 and also spread beyond species border to all imipenem-resistant genospecies 3 (2), 13TU (2), and 10 (

208 Imipenem-resistant Pseudomonas aeruginosa (IRPA) is an e

209 Seven imipenem-resistant Pseudomonas aeruginosa isolates were

210 ncomitant 68.7% increase in the incidence of imipenem-resistant Pseudomonas aeruginosa occurred throu

211 were susceptible to amikacin, ciprofloxacin, imipenem, rifampin, trimethoprim-sulfamethoxazole (TMP-S

212 Oxa-23 demonstrates changes in meropenem or imipenem sensitivity in strain AB5075.

213 romogenic substrates (CENTA, nitrocefin, and imipenem), showing improved sensitivity and kinetic para

214 ia coli and pretreatment with vancomycin and imipenem significantly modulated the susceptibility to t

215 t, which does not require the preparation of imipenem solution and has a shelf life of 2 years.

216 as it requires frequent preparation of fresh imipenem solution.

217 f the substrates ampicillin, ceftazidime and imipenem suggests that the substrate is able to bind to

218 ciprofloxacin, clarithromycin, doxycycline, imipenem, sulfamethoxazole, and tobramycin (M. chelonae

219 aphylococcus aureus, 20% that reported <100% imipenem susceptibility for Escherichia coli, and 37% th

220 nd levofloxacin and tigecycline (both >96%); imipenem susceptibility was low (32%) in Africa while mi

221 These isolates became imipenem susceptible when the chromosomal oprD lesion wa

222 a previous surveillance culture that grew an imipenem-susceptible P. aeruginosa (ISPA) and a subseque

223 Five non-imipenem-susceptible strains were identified (MIC, 8 mic

224 (CA) for penicillin-imipenem and ampicillin-imipenem tested with E. faecalis and E. faecium by BMD w

225 Using the DD method, CA for ampicillin-imipenem tested with E. faecalis and E. faecium was >/=9

226 ed two- to threefold lower concentrations of imipenem than expected and resulted in artifactual two-

227 At high concentrations of imipenem that select for phenotypically wild-type mutant

228 In contrast, imipenem treatment of E. coli-cocultured macrophages doe

229 CLS guidelines for susceptibility testing of imipenem versus enterococci.

230 ate for broth microdilution (BMD) testing of imipenem versus Enterococcus species, 633 strains of E.

231 92% for other enterococci; CA for penicillin-imipenem was 91% for E. faecalis, 98% for E. faecium, an

232 Fosfomycin plus imipenem was an effective and safe combination when used

233 The combination of ampicillin with imipenem was highly active (an additional 5 log10 reduct

234 itivities (95% confidence interval [CI]) for imipenem were 82% (74%, 89%) and 92% (85%, 97%) for PCR/

235 Resistance sensitivities (95% CI) for imipenem were 95% (88%, 98%) and 88% (80%, 94%) for PCR/

236 Isolates that tested as susceptible to imipenem were not uncommon among carbapenemase-positive

237 of Pseudomonas aeruginosa with resistance to imipenem were traced to a defective lot of microdilution

238 f the carbapenems, the most useful agent was imipenem, where a zone diameter of </= 23 mm as a predic

239 Imipenem, which has a greater affinity for penicillin-bi

240 rategies were used for the administration of imipenem, which has broad-spectrum coverage of enteric b

241 Of these, imipenem, which has demonstrable anti-tubercular activit

242 mpound strongly affected by MexB contrary to imipenem, which is apparently poorly transported by the

243 es-apparently related to in vivo exposure to imipenem, which was also used during a period of chemoth

244 r affinity to the distal binding pocket than imipenem while both compounds are weakly bound to the pr